603 related articles for article (PubMed ID: 17875755)
1. The B7 family and cancer therapy: costimulation and coinhibition.
Zang X; Allison JP
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5271-9. PubMed ID: 17875755
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T-lymphocyte-associated antigen-4.
Hodi FS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
[TBL] [Abstract][Full Text] [Related]
3. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
4. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
5. Functional hierarchy and relative contribution of the CD28/B7 and ICOS/B7-H2 costimulatory pathways to T cell-mediated delayed-type hypersensitivity.
Wong SC; Tan AH; Lam KP
Cell Immunol; 2009; 256(1-2):64-71. PubMed ID: 19249753
[TBL] [Abstract][Full Text] [Related]
6. B7.1 costimulation increases T-cell proliferation and cytotoxicity via selective expansion of specific variable alpha and beta genes of the T-cell receptor.
Chan AK; Goedegebuure PS; von Bernstorff W; Carritte AL; Chung M; Stewart RA; Montgomery L; Spanjaard RA; McKenzie AB; Eberlein TJ
Surgery; 2000 Mar; 127(3):342-50. PubMed ID: 10715992
[TBL] [Abstract][Full Text] [Related]
7. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
8. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cheuk AT; Mufti GJ; Guinn BA
Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
[TBL] [Abstract][Full Text] [Related]
9. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
10. CD28/B7 system of T cell costimulation.
Lenschow DJ; Walunas TL; Bluestone JA
Annu Rev Immunol; 1996; 14():233-58. PubMed ID: 8717514
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the involvement of T cell costimulation through the B-7/CD28 pathway in atherosclerotic plaques from apolipoprotein E knockout mice.
Afek A; Harats D; Roth A; Keren G; George J
Exp Mol Pathol; 2004 Jun; 76(3):219-23. PubMed ID: 15126104
[TBL] [Abstract][Full Text] [Related]
12. IMGT Colliers de Perles and IgSF domain standardization for T cell costimulatory activatory (CD28, ICOS) and inhibitory (CTLA4, PDCD1 and BTLA) receptors.
Garapati VP; Lefranc MP
Dev Comp Immunol; 2007; 31(10):1050-72. PubMed ID: 17391759
[TBL] [Abstract][Full Text] [Related]
13. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
Habib-Agahi M; Jaberipour M; Searle PF
Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
[TBL] [Abstract][Full Text] [Related]
14. B7-1-HSA (CD80-CD24), a recombinant hybrid costimulatory molecule retains ligand binding and costimulatory functions.
Wang YC; Sashidharamurthy R; Nagarajan S; Selvaraj P
Immunol Lett; 2006 Jun; 105(2):185-92. PubMed ID: 16621031
[TBL] [Abstract][Full Text] [Related]
15. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
Liu A; Hu P; Khawli LA; Epstein AL
J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
[TBL] [Abstract][Full Text] [Related]
16. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman A; Yellin M; Keler T
Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
[TBL] [Abstract][Full Text] [Related]
17. The B7/CD28 costimulatory family in autoimmunity.
Keir ME; Sharpe AH
Immunol Rev; 2005 Apr; 204():128-43. PubMed ID: 15790355
[TBL] [Abstract][Full Text] [Related]
18. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of T cell response to tumors by targeting on costimulatory pathway.
Chen L
Leukemia; 1997 Apr; 11 Suppl 3():567-9. PubMed ID: 9209456
[TBL] [Abstract][Full Text] [Related]
20. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties.
Bhatia S; Edidin M; Almo SC; Nathenson SG
Immunol Lett; 2006 Apr; 104(1-2):70-5. PubMed ID: 16413062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
